Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
Ard-101
Prader-Willi Syndrome, Hyperphagia In Prader-Willi Syndrome, Hyperphagia
Phase III
Recruiting
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
Sep 21, 2025
―
Ard-101
Prader-Willi Syndrome, Hyperphagia
Phase III
Recruiting
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
Feb 13, 2025
―
Low Dose Ard-501, High Dose Ard-501
Autism Spectrum Disorder
Phase II
Completed
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
Oct 20, 2023
―
Ard-101
Obesity, Weight Gain, Bariatric Surgery
Phase II
Completed
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
Jan 03, 2022
―
Ard-101
Prader-Willi Syndrome
Phase II
Completed
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
Nov 30, 2021
―
Ard-101
Obesity
Phase II
Completed
Study to Evaluate ARD-101 in Adults With Obesity
Oct 19, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Aardvark Therapeutics, Inc. (AARD) have in its pipeline
AARD is currently developing the following drugs: Ard-101, Ard-101, Low Dose Ard-501, High Dose Ard-501. These drug candidates are in various stages of clinical development as the company works toward FDA approval.